What meningococcal conjugate vaccine (MenACWY) is recommended for a 12‑month‑old infant and what is the appropriate dosing and administration schedule?

Meningococcal Conjugate Vaccine for 12-Month-Old Infant

For a 12-month-old infant requiring meningococcal conjugate vaccination, use MenACWY-CRM (Menveo) as a 2-dose series with the second dose given at least 12 weeks after the first dose, or use MenACWY-D (Menactra) as a 2-dose series at least 12 weeks apart if the infant is ≥9 months old. 1

Vaccine Selection and Dosing Schedule

The ACIP 2020 guidelines provide clear direction for infants aged 12 months (falling within the 2-23 month age bracket):

MenACWY-CRM (Menveo) - Preferred Option for 12-Month-Olds

• If first dose given at 7-23 months: Administer 2 doses total, with the second dose given ≥12 weeks after the first dose AND after the 1st birthday 1
• Since your patient is already 12 months old, give the first dose now and the second dose at approximately 15 months of age (at least 12 weeks later)
• Licensed for use starting at 2 months of age 1

MenACWY-D (Menactra) - Alternative Option

• For infants ≥9 months: Administer 2 doses ≥12 weeks apart 1
• Licensed for ages 9 months-55 years 1

MenACWY-TT (MenQuadfi) - NOT Recommended

• Licensed only for persons ≥2 years of age 1
• Should not be used in a 12-month-old infant

Critical Clinical Considerations

Timing with Other Vaccines

MenACWY-D (Menactra) has important interaction concerns:

• Should be given either before or at the same time as DTaP to avoid interference with immune response 1
• Can be given at any time relative to Tdap or Td

High-Risk Populations - Special Precautions

For infants with functional/anatomic asplenia or HIV infection:

• Do NOT use MenACWY-D (Menactra) before age 2 years due to interference with pneumococcal conjugate vaccine (PCV) response 1
• If MenACWY-D must be used in these populations, wait at least 4 weeks after completion of all PCV doses 1
• Use MenACWY-CRM (Menveo) instead for these high-risk infants under 2 years - it does not have this restriction 2

Who Needs Vaccination at 12 Months?

Routine meningococcal vaccination is not recommended for all 12-month-olds. Only vaccinate infants at increased risk for meningococcal disease 2:

• Complement component deficiencies (C3, C5-C9, properdin, factor D, factor H)
• Complement inhibitor use (eculizumab, ravulizumab)
• Functional or anatomic asplenia (including sickle cell disease)
• HIV infection
• Travel to or residence in hyperendemic/epidemic areas
• Microbiologists routinely exposed to Neisseria meningitidis
• Outbreak situations

Immunogenicity Evidence

Research demonstrates strong immune responses with the 2-dose infant series:

• After 2 doses of MenACWY-CRM at 7-9 and 12 months, 88-100% of infants achieved protective antibody levels (hSBA ≥1:8) for serogroups C, W, and Y, with 88% for serogroup A 3
• The 2-dose schedule produces robust anamnestic responses and is well-tolerated 4, 5, 3

Common Pitfalls to Avoid

1. Don't use MenACWY-TT in infants under 2 years - it's not licensed for this age group
2. Don't give MenACWY-D to high-risk infants with asplenia or HIV before age 2 - use MenACWY-CRM instead
3. Don't forget the second dose - a single dose at 12 months provides suboptimal protection; the second dose is essential
4. Don't confuse this with routine adolescent vaccination - most healthy 12-month-olds do NOT need meningococcal vaccine unless they have specific risk factors